Sign inJoin waitlistJoin the waitlist

OO

Owen O’Connor

Physician · White Plains Hospital

Credentials: · · ·

History

White Plains Hospital
2021–Present

Medical Oncology
1997–1999
Internal Medicine
1994–1997
Rutgers New Jersey Med Sch
1990–1994

Research

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
Journal of Clinical Oncology · 2005 · 769 citations
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour…
The Lancet Oncology · 2010 · 731 citations
Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model
Cell chemical biology · 2019 · 631 citations

Enrica Marchi
35 papers
AS
Ahmed Sawas
24 papers · 2 as a fellow
Jasmine Zain
24 papers
SH
Steven Horwitz
24 papers
Changchun Deng
21 papers
Govind Bhagat
20 papers
Jennifer Amengual
19 papers
AZ
Andrew Zelenetz
18 papers
CP
Carol Portlock
16 papers
Craig Moskowitz
16 papers
HM
Helen Ma
16 papers · 11 as a fellow
DS
David Straus
15 papers

Grants

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-Cell Lymphoma (PTCL).
Food and Drug Administration · R01
Contact PI · $1.6M · University of Virginia
2020–2027
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $290.2K · Columbia University Health Sciences
1997–2014
A Multicenter Phase 2 Trial of Praltrexate w/Relapsed
Food and Drug Administration · R01
Contact PI · $697.2K · New York University School of Medicine
2007–2011

Clinical trials

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Principal investigator · Terminated · Phase 1, Phase 2
Columbia University
2013–2020
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Principal investigator · Completed · Phase 1, Phase 2
Columbia University
2012–2018
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Principal investigator · Completed · Phase 2
Spectrum Pharmaceuticals, Inc
2008–2014
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Principal investigator · Completed · Phase 1
Columbia University
2008–2015